Astria Therapeutics Inc

General ticker "ATXS" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $562.9M

Astria Therapeutics Inc follows the US Stock Market performance with the rate: 15.5%.

Estimated limits based on current volatility of 2.7%: low 9.19$, high 9.71$

Factors to consider:

  • Current price 37.3% above estimated high
  • Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [2.32$, 6.93$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.17$, 3.79$]

Financial Metrics affecting the ATXS estimates:

  • Negative: Non-GAAP EPS, $ of -2.34 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -28.98 <= 2.35
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: negative Net income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Inventory ratio change, % of 0 <= 0

Similar symbols

Short-term ATXS quotes

Long-term ATXS plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $194.98MM $53.50MM $83.03MM
Operating Income $-194.98MM $-53.50MM $-83.03MM
Non-Operating Income $0.06MM $1.67MM $10.14MM
R&D Expense $15.55MM $34.26MM $57.33MM
Income(Loss) $-194.91MM $-51.83MM $-72.89MM
Profit(Loss) $-194.91MM $-51.83MM $-72.89MM
Stockholders Equity $122.31MM $221.22MM $243.12MM
Assets $127.51MM $230.63MM $254.67MM
Operating Cash Flow $-30.15MM $-43.53MM $-68.44MM
Capital expenditure $0.02MM $0.09MM $0.03MM
Investing Cash Flow $-12.55MM $-167.13MM $135.05MM
Financing Cash Flow $104.28MM $144.72MM $88.40MM
Earnings Per Share* $-3.38 $-3.43 $-2.42

* EPS are Split Adjusted, recent splits may be reflected with a delay.